Pfizer Inc PFE

$28.37 -0.03 (-0.11%)

Valuation

Market cap
161,186,784,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.12
Forward PE
9.35
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
26,828,408
Avg volume
34,774,676
Day's range
$28.13 – $28.61
Shares out
5,699,674,000
Stochastic %K
70%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

MrPeanutEsquire Oct 13, 9:40 PM
$PFE The waiting is the hardest part
1 replies
CecilGleason Oct 13, 9:28 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $PFE $MA $ACN x
0 replies
thatsolardude365 Oct 13, 9:18 PM
$PFE: filed a Chantix claim? Your share comes from a consumer pool capped at 20% of the net $44M fund, pro rata on what you paid, never more. Final approval hearing is today; keep pharmacy records handy. Open Class Actions.
0 replies
Typecheck Oct 13, 9:12 PM
$PFE saw a spike aftermarket to 30+.
2 replies
Quantumup Oct 13, 8:34 PM
Stifel on $IDYA said -- We are resuming coverage of IDYA with a Buy rating and $48 target price. $PFE $NVS REPL ESAIY AMGN AZN ABBV MRK DSNKY ZLAB Stifel added—IDYA is on the cusp of transitioning to a commercial-stage company in 2027 with darovasertib + crizotinib in 1L metastatic uveal melanoma; the IDYA combo is set to become the new SoC in HLA-A*02:01-negative mUM with HLA-agnostic label upside seeming increasingly likely per recent comments from management. Given the relatively small TAM in 1L mUM, further IDYA upside will depend heavily on darovasertib expansion into primary UM and near-term de-risking catalysts for earlier-stage pipeline, especially DLL3 TOPO1 ADC (IDE849) & PRMT5 inhibitor (IDE892). Cash runway into 2030.
0 replies
CecilGleason Oct 13, 7:55 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $S $PFE $BTBT u
0 replies
biolover Oct 13, 6:33 PM
$VKTX Institutuons selling right and left indiscriminately in all biotech. Vk will prevail. I will worry at this point if $LLY MC collapses > 75%. Then there is problem in obesity. Although Viking will have an impact on Lilly MC and I believe Lilly mgt knows that and watching carefully. They know assets well and that why Lilly attempted to acquire Viking in early 2024 while Ricks mocked $PFE $NVO battle on Metsera. 
1 replies
SaylorsPonz Oct 13, 5:35 PM
$PFE The Hair Twirling Semi Genius Now A Daddy in trouble again
0 replies